| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly's product and service development is currently centered on significant advancements in therapeutic offerings, particularly in obesity treatment and gastrointestinal health. The launch of new formulations and the positive long-term outcomes of existing products, like Omvoh, underscore the company's commitment to innovation. Success in the drug pipeline development further positions Eli Lilly for enhanced market performance. Overall, the focus on new therapies and improved efficacy data suggests a strong outlook for the company's future products. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 0.4 is modestly bullish. The market sentiment at 0.1 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. LLY is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for sector is at 0.8, and the negative at -0.7 on 2026-02-23. The forces of Sentiment towards Fundamentals (3.4), Option Sentiment (0.8), Stock Price Trend (0.4), Sector Price Trend (0.1), and Price Level Sentiment (0) will drive up the price. The forces of Valuation Sentiment (-1), and Market Risk Appetite (-3.2) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-23 | 0%(0%) | 1058.41 | 2.14% | 74 | 4.83% | 0.01% | 0.4 | 0.7 | 1.7% | 0.1 | Long | 55% | 3.4 | 4.5 |
| 2026-02-22 | 0%(0%) | -1.1 | 0.7 | 0.3 | 4.6 | -1 | ||||||||
| 2026-02-21 | 0%(0%) | -1.1 | 0.7 | 0.3 | 4.6 | -1 | ||||||||
| 2026-02-20 | 0%(0%) | 1009.69 | 2.28% | 21 | -1.33% | -0.11% | -1.1 | -0.2 | 0.5% | 0.6 | Short | 55% | 4.8 | -1 |
| 2026-02-19 | 0%(0%) | 1023.26 | 2.41% | 32 | 0.28% | -0.81% | -0.9 | 0.1 | 1% | 0.1 | Wait | 50% | 4.5 | -1 |
| 2026-02-18 | 0%(0%) | 1020.37 | 2.51% | 27 | -1.55% | 0.16% | 0 | -0.3 | 1.3% | 0.2 | Short | 55% | 4.3 | -1 |
| 2026-02-17 | 0%(0%) | 1036.44 | 2.41% | 42 | -0.36% | -0.07% | -0.3 | -0.4 | 0.4% | 0.4 | Short | 55% | 4.7 | 7 |
| 2026-02-16 | 0%(0%) | -0.3 | -0.4 | -0.1 | 4.5 | -1 | ||||||||
| 2026-02-15 | 0%(0.1%) | -0.3 | -0.4 | -0.2 | 4.1 | -1 | ||||||||
| 2026-02-14 | 0%(0.1%) | -0.3 | -0.4 | -0.2 | 4 | -1 | ||||||||
| Long is the preferred trading strategy with 55% chance of being right. Improving trend sentiment and positive hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| 2026-02-23 17:49:18 The rise in Eli Lilly's shares reflects positive market sentiment following their product's performance against a competitor. |
| 2026-02-23 17:49:18 Eli Lilly's Zepbound outperforming Novo's drug indicates a successful product development that may enhance Eli Lilly's market performance. |
| 2026-02-23 17:49:18 The rivalry between Eli Lilly and Novo Nordisk highlights the intense competition in the obesity drug market, especially with recent trial results affecting market positions. |
| 2026-02-23 17:02:12 Investors are adjusting their holdings in Novo Nordisk and Eli Lilly based on the recent trial outcomes and stock performance. |
| 2026-02-23 17:02:12 The competition between Novo Nordisk and Eli Lilly is reshaping the obesity drug market, with shifting market positions and consumer options. |
| 2026-02-23 17:02:12 The failures in drug trials for Novo Nordisk resulted in significant drops in its stock value while Eli Lilly's stock surged. |
| 2026-02-23 17:02:12 Eli Lilly's drug Zepbound gained approval and is poised to dominate the obesity treatment market, capitalizing on Novo Nordisk's setback. |
| 2026-02-23 17:02:12 Novo Nordisk's drug CagriSema failed to prove its effectiveness against Eli Lilly's tirzepatide, significantly impacting its market value. |
| 2026-02-23 13:48:46 The rise in Eli Lilly's stock price following its market performance and the decline of its competitor. |
| 2026-02-23 13:48:46 The competitive dynamics between Eli Lilly and Novo Nordisk in the obesity market, highlighting Lilly's recent gains. |
| 2026-02-23 11:49:29 The mention of President Trump's tariffs reflects political influence on market dynamics and investor sentiment. |
| 2026-02-23 11:49:29 Eli Lilly's competitive advantage over Novo Nordisk in the obesity drug market highlights the intense competition in this sector. |
| 2026-02-23 11:49:29 Eli Lilly's launch of a new formulation of its obesity drug Zepbound indicates progress in product development aimed at improving user convenience. |